Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity. 2023

Annemarie Laumaea, and Lorie Marchitto, and Shilei Ding, and Guillaume Beaudoin-Bussières, and Jérémie Prévost, and Romain Gasser, and Debashree Chatterjee, and Gabrielle Gendron-Lepage, and Halima Medjahed, and Hung-Ching Chen, and Amos B Smith, and Haitao Ding, and John C Kappes, and Beatrice H Hahn, and Frank Kirchhoff, and Jonathan Richard, and Ralf Duerr, and Andrés Finzi
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada. Electronic address: annemarie.laumaea@umontreal.ca.

HIV-1 envelope (Env) conformation determines the susceptibility of infected CD4+ T cells to antibody-dependent cellular cytotoxicity (ADCC). Upon interaction with CD4, Env adopts more "open" conformations, exposing ADCC epitopes. HIV-1 limits Env-CD4 interaction and protects infected cells against ADCC by downregulating CD4 via Nef, Vpu, and Env. Limited data exist, however, of the role of these proteins in downmodulating CD4 on infected macrophages and how this impacts Env conformation. While Nef, Vpu, and Env are all required to efficiently downregulate CD4 on infected CD4+ T cells, we show here that any one of these proteins is sufficient to downmodulate most CD4 from the surface of infected macrophages. Consistent with this finding, Nef and Vpu have a lesser impact on Env conformation and ADCC sensitivity in infected macrophages compared with CD4+ T cells. However, treatment of infected macrophages with small CD4 mimetics exposes vulnerable CD4-induced Env epitopes and sensitizes them to ADCC.

UI MeSH Term Description Entries
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D054299 env Gene Products, Human Immunodeficiency Virus Proteins encoded by the ENV GENE of the HUMAN IMMUNODEFICIENCY VIRUS. env Gene Products, HIV,env Proteins, Human Immunodeficiency Virus,envelope Proteins, Human Immunodeficiency Virus

Related Publications

Annemarie Laumaea, and Lorie Marchitto, and Shilei Ding, and Guillaume Beaudoin-Bussières, and Jérémie Prévost, and Romain Gasser, and Debashree Chatterjee, and Gabrielle Gendron-Lepage, and Halima Medjahed, and Hung-Ching Chen, and Amos B Smith, and Haitao Ding, and John C Kappes, and Beatrice H Hahn, and Frank Kirchhoff, and Jonathan Richard, and Ralf Duerr, and Andrés Finzi
March 2020, ACS medicinal chemistry letters,
Annemarie Laumaea, and Lorie Marchitto, and Shilei Ding, and Guillaume Beaudoin-Bussières, and Jérémie Prévost, and Romain Gasser, and Debashree Chatterjee, and Gabrielle Gendron-Lepage, and Halima Medjahed, and Hung-Ching Chen, and Amos B Smith, and Haitao Ding, and John C Kappes, and Beatrice H Hahn, and Frank Kirchhoff, and Jonathan Richard, and Ralf Duerr, and Andrés Finzi
May 2015, Proceedings of the National Academy of Sciences of the United States of America,
Annemarie Laumaea, and Lorie Marchitto, and Shilei Ding, and Guillaume Beaudoin-Bussières, and Jérémie Prévost, and Romain Gasser, and Debashree Chatterjee, and Gabrielle Gendron-Lepage, and Halima Medjahed, and Hung-Ching Chen, and Amos B Smith, and Haitao Ding, and John C Kappes, and Beatrice H Hahn, and Frank Kirchhoff, and Jonathan Richard, and Ralf Duerr, and Andrés Finzi
May 2017, AIDS research and human retroviruses,
Annemarie Laumaea, and Lorie Marchitto, and Shilei Ding, and Guillaume Beaudoin-Bussières, and Jérémie Prévost, and Romain Gasser, and Debashree Chatterjee, and Gabrielle Gendron-Lepage, and Halima Medjahed, and Hung-Ching Chen, and Amos B Smith, and Haitao Ding, and John C Kappes, and Beatrice H Hahn, and Frank Kirchhoff, and Jonathan Richard, and Ralf Duerr, and Andrés Finzi
May 2019, Journal of virology,
Annemarie Laumaea, and Lorie Marchitto, and Shilei Ding, and Guillaume Beaudoin-Bussières, and Jérémie Prévost, and Romain Gasser, and Debashree Chatterjee, and Gabrielle Gendron-Lepage, and Halima Medjahed, and Hung-Ching Chen, and Amos B Smith, and Haitao Ding, and John C Kappes, and Beatrice H Hahn, and Frank Kirchhoff, and Jonathan Richard, and Ralf Duerr, and Andrés Finzi
June 2017, Journal of virology,
Annemarie Laumaea, and Lorie Marchitto, and Shilei Ding, and Guillaume Beaudoin-Bussières, and Jérémie Prévost, and Romain Gasser, and Debashree Chatterjee, and Gabrielle Gendron-Lepage, and Halima Medjahed, and Hung-Ching Chen, and Amos B Smith, and Haitao Ding, and John C Kappes, and Beatrice H Hahn, and Frank Kirchhoff, and Jonathan Richard, and Ralf Duerr, and Andrés Finzi
January 2016, EBioMedicine,
Annemarie Laumaea, and Lorie Marchitto, and Shilei Ding, and Guillaume Beaudoin-Bussières, and Jérémie Prévost, and Romain Gasser, and Debashree Chatterjee, and Gabrielle Gendron-Lepage, and Halima Medjahed, and Hung-Ching Chen, and Amos B Smith, and Haitao Ding, and John C Kappes, and Beatrice H Hahn, and Frank Kirchhoff, and Jonathan Richard, and Ralf Duerr, and Andrés Finzi
February 2016, Journal of virology,
Annemarie Laumaea, and Lorie Marchitto, and Shilei Ding, and Guillaume Beaudoin-Bussières, and Jérémie Prévost, and Romain Gasser, and Debashree Chatterjee, and Gabrielle Gendron-Lepage, and Halima Medjahed, and Hung-Ching Chen, and Amos B Smith, and Haitao Ding, and John C Kappes, and Beatrice H Hahn, and Frank Kirchhoff, and Jonathan Richard, and Ralf Duerr, and Andrés Finzi
September 2019, EBioMedicine,
Annemarie Laumaea, and Lorie Marchitto, and Shilei Ding, and Guillaume Beaudoin-Bussières, and Jérémie Prévost, and Romain Gasser, and Debashree Chatterjee, and Gabrielle Gendron-Lepage, and Halima Medjahed, and Hung-Ching Chen, and Amos B Smith, and Haitao Ding, and John C Kappes, and Beatrice H Hahn, and Frank Kirchhoff, and Jonathan Richard, and Ralf Duerr, and Andrés Finzi
July 2020, Cell death & disease,
Annemarie Laumaea, and Lorie Marchitto, and Shilei Ding, and Guillaume Beaudoin-Bussières, and Jérémie Prévost, and Romain Gasser, and Debashree Chatterjee, and Gabrielle Gendron-Lepage, and Halima Medjahed, and Hung-Ching Chen, and Amos B Smith, and Haitao Ding, and John C Kappes, and Beatrice H Hahn, and Frank Kirchhoff, and Jonathan Richard, and Ralf Duerr, and Andrés Finzi
January 1999, Methods in molecular medicine,
Copied contents to your clipboard!